Ryan Jason, Meng Stephen
Pat and Jim Calhoun Cardiology Center, UCONN Health Center, 263 Farmington Avenue, Farmington, CT 06030, USA.
Curr Heart Fail Rep. 2013 Sep;10(3):185-9. doi: 10.1007/s11897-013-0142-z.
The Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARRESS-HF) trial was a prospective, randomized study comparing ultrafiltration versus pharmacological therapy in the treatment of acute decompensated heart failure (ADHF) complicated by cardiorenal syndrome Bart et al. (N Eng J Med 367:2296-2304, 1). The study found that ultrafiltration was inferior to pharmacological therapy, resulting in a significant increase in serum creatinine and serious adverse events while producing no significant difference in weight loss. The CARRESS trial calls into question the viability of ultrafiltration as a preferable treatment strategy in ADHF patients with cardiorenal syndrome.
急性失代偿性心力衰竭的心肾挽救研究(CARRESS-HF)试验是一项前瞻性随机研究,比较了超滤与药物治疗在治疗并发心肾综合征的急性失代偿性心力衰竭(ADHF)中的效果(Bart等人,《新英格兰医学杂志》367:2296 - 2304,1)。该研究发现,超滤不如药物治疗,导致血清肌酐显著升高和严重不良事件增加,同时在体重减轻方面没有显著差异。CARRESS试验对超滤作为并发心肾综合征的ADHF患者首选治疗策略的可行性提出了质疑。